Pain Management in Colorectal Cancer Patients

Introduction to Pain Management

The American Society of Clinical Oncology recommends pain management in colorectal cancer patients should follow the WHO analgesic ladder approach, with regular assessment and a combination of pharmacological and non-pharmacological interventions tailored to pain intensity and type 1, 2

The European Society for Medical Oncology suggests all colorectal cancer patients should be evaluated for pain at every clinical visit using standardized self-reporting tools such as visual analog scales (VAS), numerical rating scales (NRS), or verbal rating scales (VRS) 3, 2
Pain assessment should characterize the type (nociceptive, neuropathic), location, intensity, duration, temporal patterns, and factors that relieve or exacerbate pain 1, 4
Over 80% of cancer patients with advanced metastatic disease experience pain, primarily from direct tumor infiltration, while approximately 20% of pain may be attributed to effects of surgery, radiotherapy, or chemotherapy 5, 2

The National Comprehensive Cancer Network recommends use of non-opioid analgesics such as acetaminophen/paracetamol (maximum 4000 mg/day) or NSAIDs 3, 6
When using NSAIDs over a prolonged period, gastroprotection is recommended to prevent GI toxicity 5, 1
Use NSAIDs with caution in patients with renal impairment, heart failure, hypertension, or at risk of bleeding 5, 1

The American Pain Society suggests adding weak opioids (codeine, dihydrocodeine, tramadol) to non-opioid analgesics, or using low doses of strong opioids 7, 2
Consider controlled-release formulations of codeine, dihydrocodeine, tramadol, morphine, or oxycodone in dosages appropriate for moderate pain 5, 8

The European Association for Palliative Care recommends use of strong opioids such as morphine (preferred first-line), hydromorphone, oxycodone, or fentanyl 6, 2

The American Society of Clinical Oncology recommends providing around-the-clock dosing for persistent pain rather than "as needed" administration 1, 2
Include "breakthrough" doses (typically 10-15% of total daily dose) for transient pain exacerbations 1, 2
Titrate doses rapidly to achieve effective pain control, and adjust the baseline opioid regimen if more than four breakthrough doses are needed daily 2, 4

The National Comprehensive Cancer Network suggests considering anticonvulsants (gabapentin, pregabalin), antidepressants (tricyclics, SNRIs), or corticosteroids for neuropathic pain 1
Consider bone-modifying agents (bisphosphonates, denosumab) for bone pain 1, 2

The American Society for Radiation Oncology recommends considering radiation therapy for localized bone pain 1, 2
Consider surgical stabilization for impending fractures 2, 4
Consider nerve blocks for specific pain syndromes 1
Consider vertebral augmentation (vertebroplasty/kyphoplasty) for vertebral pain with instability 1

The European Society for Medical Oncology recommends obtaining regular pain ratings and documenting in medical records 1, 2
Adjust treatment based on changes in pain intensity, side effects, and disease progression 1, 4

The American Geriatrics Society recommends avoiding underestimating pain severity in patients with cognitive impairment 4
Failing to recognize that most cancer patients have multiple types of cancer-related pain 4
Inadequate titration of opioids leading to poor pain control 4
Not addressing opiophobia in patients and families 4
Neglecting to provide prophylactic management of opioid side effects 4
Overlooking the psychosocial impact of pain on patients 4